MENU
+Compare
VTGN
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$2.92
Change
-$0.00 (-0.00%)
Capitalization
81.3M

VTGN VistaGen Therapeutics Forecast, Technical & Fundamental Analysis

a developer of embryonic stem cells for drug discovery and development

Industry Biotechnology
VTGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for VTGN with price predictions
Jan 08, 2025

VTGN's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for VTGN moved out of overbought territory on January 07, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VTGN broke above its upper Bollinger Band on December 30, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VTGN entered a downward trend on December 19, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 24, 2024. You may want to consider a long position or call options on VTGN as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for VTGN just turned positive on December 23, 2024. Looking at past instances where VTGN's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

VTGN moved above its 50-day moving average on December 30, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VTGN crossed bullishly above the 50-day moving average on January 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where VTGN advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.874) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). VTGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (101.010) is also within normal values, averaging (264.084).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VTGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
VTGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

VTGN is expected to report earnings to fall 94.68% to -5 cents per share on June 27

VistaGen Therapeutics VTGN Stock Earnings Reports
Q1'23
Est.
$-0.05
Q2'23
Beat
by $1.31
Q4'22
Beat
by $0.02
Q3'22
Missed
by $0.01
Q2'22
Missed
by $0.02
The last earnings report on August 10 showed earnings per share of -93 cents, beating the estimate of -225 cents. With 108.72K shares outstanding, the current market capitalization sits at 81.30M.
A.I. Advisor
published General Information

General Information

a developer of embryonic stem cells for drug discovery and development

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
343 Allerton Avenue
Phone
+1 650 577-3600
Employees
33
Web
https://www.vistagen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VIGL1.930.04
+2.12%
Vigil Neuroscience
MBIN38.670.77
+2.03%
Merchants Bancorp
ORCL161.031.49
+0.93%
Oracle Corp
FMC53.43-0.10
-0.19%
FMC Corp
MLYS9.24-0.26
-2.74%
Mineralys Therapeutics

VTGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VTGN has been loosely correlated with ATAI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if VTGN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTGN
1D Price
Change %
VTGN100%
N/A
ATAI - VTGN
42%
Loosely correlated
+5.04%
SRRK - VTGN
40%
Loosely correlated
-1.75%
MGTX - VTGN
38%
Loosely correlated
+5.56%
ABCL - VTGN
38%
Loosely correlated
+1.02%
ABOS - VTGN
38%
Loosely correlated
+2.48%
More